Medical Chemistry, Pharmaceuticals and Small Molecule

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Medical Chemistry

Pharmaceuticals

Small Molecule

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

JUNE 16, 2025

However, due to its unique biology and structural complexity, PAR2 has proven notoriously difficult for the pharmaceutical industry to effectively target. DT-9046 is an orally delivered small molecule that has reached pre-IND studies – making Domain the first company to successfully advance a small molecule candidate targeting PAR2.

Disease

Disease Therapies Small Molecule Immune Response

Outsmarting immune suppression through GPCR innovation

Drug Target Review

JULY 18, 2025

Whether we are working with small molecules or larger biologics, our platform enables a precise design of innovative drug candidates with highly differentiated profiles.” Prior to joining Domain, Stephan established and led the Medicinal Chemistry Department at Faust Pharmaceuticals and was a senior scientist at Evotec.

Medical Chemistry

Medical Chemistry Small Molecule Therapies Clinical Development

Drug Discovery Digest

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Outsmarting immune suppression through GPCR innovation

Stay Connected